Epidemic Intelligence Service, CDC, United States; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States.
Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States.
Vaccine. 2018 Jan 4;36(2):306-312. doi: 10.1016/j.vaccine.2017.10.104. Epub 2017 Dec 2.
Highly pathogenic avian influenza A (HPAI) viruses found in poultry and wild birds occasionally infect humans and can cause serious disease. In 2014, the Advisory Committee on Immunization Practices (ACIP) reviewed data from one licensed ASO3-adjuvanted influenza A(H5N1) vaccine for consideration of use during inter-pandemic periods among persons with occupational exposure. To guide vaccine policy decisions, we conducted a survey of laboratory workers to assess demand for HPAI vaccination.
We designed an anonymous web survey (EpiInfo 7.0) to collect information on demographics, type of work and time spent with HPAI viruses, and interest in HPAI vaccination. Eligible participants were identified from 42 entities registered with United States Department of Agriculture's Agricultural Select Agent program in 2016 and emailed electronic surveys. Personnel with Biosafety Level 3 enhanced (BSL-3E) laboratory access were surveyed. Descriptive analysis was performed.
Overall, 131 responses were received from 33 principal investigators, 26 research scientists, 24 technicians, 15 postdoctoral fellows, 6 students, and 27 others. The estimated response rate was 15% among the laboratory personnel of responding principal investigators. One hundred respondents reported working in a BSL-3E area where HPAI experiments occurred with a mean time of 5.1-11.7 h per week. Overall, 49% were interested in receiving an A(H5N1) vaccine. By role, interest was highest among students (80%) and among those who spent >50% of their time in a BSL-3E area (64%). Most (61%) of those who said they might be or were not interested in vaccine believed it would not provide additional protection to current safety practices.
Half of responding laboratory workers was interested in receiving an influenza A(H5N1) vaccine. HPAI vaccination of laboratory workers at risk of occupational exposure could be used along with existing safety practices to protect this population.
家禽和野禽中发现的高致病性禽流感（HPAI）病毒偶尔会感染人类，并可导致严重疾病。2014 年，免疫实践咨询委员会（ACIP）审查了一种已许可的 ASO3 佐剂流感 A（H5N1）疫苗的数据，以考虑在大流行期间对职业接触者使用。为了指导疫苗政策决策，我们对实验室工作人员进行了调查，以评估对 HPAI 疫苗接种的需求。
我们设计了一项匿名网络调查（EpiInfo 7.0），以收集有关人口统计学、工作类型和与 HPAI 病毒接触时间以及对 HPAI 疫苗接种兴趣的信息。从 2016 年在美国农业部农业选择剂计划下注册的 42 个实体中确定了合格的参与者，并通过电子邮件发送了电子调查。对具有生物安全 3 级增强（BSL-3E）实验室通道的人员进行了调查。进行了描述性分析。
共有来自 33 位主要研究人员、26 位研究科学家、24 位技术人员、15 位博士后研究员、6 位学生和 27 位其他人员的 131 份回复。回复的主要研究人员的实验室人员的估计回复率为 15%。有 100 名受访者报告在 BSL-3E 区域工作，该区域进行了 HPAI 实验，每周平均有 5.1-11.7 小时的工作时间。总体而言，有 49%的人有兴趣接种 A（H5N1）疫苗。按角色划分，学生的兴趣最高（80%），在 BSL-3E 区域花费时间超过 50%的人员的兴趣最高（64%）。表示可能或不感兴趣接种疫苗的人中有 61%（61%）认为，接种疫苗不会对现有安全措施提供额外的保护。
一半的实验室工作人员对接种流感 A（H5N1）疫苗感兴趣。对有职业接触风险的实验室工作人员进行 HPAI 疫苗接种，可与现有安全措施一起使用，以保护这一人群。
